Tissue Doppler Imaging and Ultrasonic Methods for Evaluating Myocardial Deformation in the Diagnosis of Hypertrophic Cardiomyopathy

Крылова, Н. С.; Демкина, А.Е.; Потешкина, Н. Г.; Хашиева, Ф. М.

doi:10.18565/cardio.2014.7.79-84

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrast-enhanced ultrasound is currently used to diagnose cardiovascular conditions, as it is non-invasive, painless, relatively cheap, has an extensive range and high-resolution (19,20). Notably, contrast-enhanced ultrasound is widely applied in the diagnosis of hypertrophic cardiomyopathy (21). Microbubbles are the most common used ultrasound contrast agent and provide a strongly reflective interface and resonate to ultrasound waves, which are easily observed (22).…”

Section: Contrast-enhanced Ultrasound With a Novel Nanoparticle Contrmentioning

confidence: 99%

Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer

Han

Jing

2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Non-small cell lung cancer (NSCLC) initiates in the non-small cells of the lung and is one of the most common types of human cancer. It is known for its rapid growth, easy migration, invasion and reoccurrence, and has the highest incidence rate of all types of cancer. Early detection of NSCLC is difficult to achieve and this is the primary reason for low survival rates in NSCLC. Contrast-enhanced ultrasound is the most common application for evaluating patients diagnosed with NSCLC. In the present study, a contrast-enhanced ultrasound combined with nanoparticles was performed with the aim of identifying patients with NSCLC at an early stage. The present study evaluated the effectiveness of administering a nanoparticle contrast agent through respiration in combination with enhanced ultrasound at improving image quality compared with traditional ultrasound. This maybe a novel method of detecting early-stage tumors in patients. There are numerous benefits to conducting diagnoses of NSCLC using contrast-enhanced ultrasound. It is a non-invasive imaging modality, induces little pain, has a low cost, an extensive range and produces high-resolution images. This means that it is safer and more beneficial to use in patients with NSCLC than conventional imaging examinations, including X-ray and bronchoscopy. Furthermore, the nanoscale microbubble contrast agent containing liposome-encapsulated epidermal growth factor receptor was inhaled by nebulization, which may lead to an enhanced ultrasound image. The sensitivity of contrast-enhanced ultrasound was investigated in mice with early stage NSCLC. The results indicated that ultrasound administrated with nanoscale microbubble enhanced sensitivity and improved image quality compared with simple ultrasound. Furthermore, enhanced ultrasound resulted in a reliable and sensitive assessment of tumor mass in early-stage tumors. Altogether, contrast-enhanced ultrasound facilitated the efficient detection of NSCLC in patients in situ at an early stage. This protocol improved the understanding of the pathophysiology of NSCLC and may be applied in the detection of early-stage tumors in patients suspected of having cancer.

show abstract

Section: Contrast-enhanced Ultrasound With a Novel Nanoparticle Contrmentioning

confidence: 99%

Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer

Han

Jing

2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…In the present study, CECT combined with targeting nanoscale microbubble contrast agent (CECT-TNCA) was introduced to detect the early stage of patients with suspected gastric cancer. Notably, CECT in conjunction with ultrasound contrast further expanded its application in the field of primary diagnosis and confirmed diagnosis ( 18 ). This clinical analysis demonstrated the potential application of CECT-TNCA for imaging modality and sensitivity improvements in the diagnosis of gastric cancer.…”

Section: Introductionmentioning

confidence: 99%

Application of novel targeting nanoparticles contrast agent combined with contrast‑enhanced computed tomography during screening for early‑phase gastric carcinoma

Zhang

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Gastric cancer is one of the most common human tumors worldwide. The biggest bottleneck is a lack of advanced and sensitive protocols for the diagnosis of patients with early-stage gastric cancer. Therefore, more sensitive methods of diagnosing gastric cancer are urgently required to improve survival rates. In this clinical study, contrast-enhanced computed tomography (CECT) with targeting nanoparticles contrast agent (CECT-TNCA) was used to diagnose early-stage gastric cancer. The specific-targeted tyrosine kinase inhibitors of gastric cancer, including platelet-derived growth factor receptor-β, Ret and Kit, were used as TNCAs. A total of 484 patients with suspected gastric cancer were voluntarily recruited to investigate the efficacy of CECT-TNCA in the diagnosis of patients with early-stage gastric cancer. Patients with suspected gastric cancer were subjected CT and CECT-TNCA to detect whether gastric tumors existed. TNCA was orally administered before CT and CECT-TNCA (20 min). Our diagnostic data revealed that CECT-TNCA improved sensitivity and provided a new protocol to diagnose tumors in patients with suspected gastric cancer at the early stage. In addition, imaging using CECT-TNCA enabled the visualization of tiny nodules in the gastric area. CECT-TNCA diagnosed 182 patients with suspected gastric cancer as tumor-free. CECT-TNCA confirmed gastric cancer in 302 patients. Our novel diagnosis indicated significantly (P<0.01) differential signal enhancement in the gastric nodules via CECT-TNCA compared with CT, suggesting higher accuracy and the accumulation of TNCA in tumor nodules in the stomach. Furthermore, survival rates of patients detected by early-diagnosis of CECT-TNCA were significantly higher than the mean five-year survival (P<0.01). In conclusion, our investigations demonstrate that the sensibility and accuracy of CT is improved through combination with liposome-encapsulated nanoparticle contrast agent for the diagnosis of early stage gastric cancer when compared with single CT detection. CECT-TNCA improves the accuracy of CT and diagnostic confidence in assessing mural enhancement in patients with suspected gastric cancer.

show abstract

Advanced myocardial characterization in hypertrophic cardiomyopathy: feasibility of CMR-based feature tracking strain analysis in a case-control study

et al. 2020

View full text Add to dashboard Cite

Tissue Doppler Imaging and Ultrasonic Methods for Evaluating Myocardial Deformation in the Diagnosis of Hypertrophic Cardiomyopathy

Cited by 3 publications

References 0 publications

Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer

Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer

Application of novel targeting nanoparticles contrast agent combined with contrast‑enhanced computed tomography during screening for early‑phase gastric carcinoma

Advanced myocardial characterization in hypertrophic cardiomyopathy: feasibility of CMR-based feature tracking strain analysis in a case-control study

Contact Info

Product

Resources

About